3-(p-Fluorobenzoyloxy)tropane
Clinical data | |
---|---|
Routes of administration | insufflated |
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C15H18FNO2 |
Molar mass | 263.312 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
3β-(p-Fluorobenzoyloxy)tropane, (8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 4-fluorobenzoic acid ester, 4-fluorotropacocaine, 3-Pseudotropyl-4-fluorobenzoate, 3-pseudotropyl-4-fluorobenzoate, pFBT) is a tropane derivative drug which acts as a local anaesthetic, having around 30% the stimulant potency of cocaine but around the same potency as a local anaesthetic. It has been investigated as a potential radiolabelled agent for studying receptor binding,[1] but was not adopted for this application. The main application for fluorotropacocaine, however, has been as a designer drug analogue of cocaine, first detected by the EMCDDA in 2008,[2][3] and subsequently sold as an ingredient of various "bath salt" powder products, usually mixed in combination with other stimulant drugs such as caffeine, dimethocaine, desoxypipradrol or substituted cathinone derivatives.[4]
See also
- Hygrine
- 4′-Fluorococaine
- Tropacocaine
References
- ↑ Ali M. Emran. New Trends in Radiopharmaceutical Synthesis, Quality Assurance, and Regulatory Control. Springer, 1991. p84. ISBN 0-306-44035-0
- ↑ Wohlfarth A, Weinmann W (May 2010). "Bioanalysis of new designer drugs". Bioanalysis. 2 (5): 965–79. doi:10.4155/bio.10.32. PMID 21083227.
- ↑ Kavanagh P, Angelov D, O'Brien J, Fox J, O'Donnell C, Christie R, et al. (January 2012). "The syntheses and characterization 3β-(4-fluorobenzoyloxy)tropane (fluorotropacocaine) and its 3α isomer". Drug Testing and Analysis. 4 (1): 33–8. doi:10.1002/dta.362. PMID 22102564.
- ↑ Reitzel LA, Dalsgaard PW, Müller IB, Cornett C (May 2012). "Identification of ten new designer drugs by GC-MS, UPLC-QTOF-MS, and NMR as part of a police investigation of a Danish internet company". Drug Testing and Analysis. 4 (5): 342–54. doi:10.1002/dta.358. PMID 22102551.